Trial Profile
A Single-blind, Placebo-controlled, Parallel Group, Single Increasing Dose Tolerance Study in Healthy Male Volunteers After Intravenous Administration of BIII 890 CL (Dosage: 0.5 mg/h - 80 mg/h), Infusion Time 1 Hour.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 24 Oct 2014
Price :
$35
*
At a glance
- Drugs Crobenetine (Primary)
- Indications Pain; Stroke
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 24 Oct 2014 New trial record